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Abstract Life expectancy statistics predict that in a couple of decades women will enjoy a mean life of 90 years. Assuming a median
age for the onset of menopause of 51, women will spend about 40 years in menopause. Harvesting and freezing ovarian cortical tissue
at a younger age to permit future transplantation for postponing menopause and its sequelae could become a possible option. However,
both medical and ethical issues need to be addressed before this can be offered as a treatment for menopause.
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The article by Andersen and Kristensen (2015), in this issue
of Reproductive BioMedicine Online, concerning the possi-
bility of prolonging endocrine ovarian activity for years after
menopause is of interest both scientiﬁcally and ethically.
According to the World Health Organization World Health
Statistics for 2014, women live longer than men all over the
world. The overall age expectancy for men in high income
countries is 75.8 years versus 60.1 years in low income coun-
tries and for women it is 82 years in high income countries
and 63.1 years in low income countries (http://www.who.int/
gho/publications/world_health_statistics). Older adults are
also living longer. Between 1990 and 2012 life expectancy for
men aged 60 increased from 16.6 years to 18.5 years and for
women from 19.7 years to 21.5 years. It is therefore very likely
that if these trends continue, in a couple of decades women
will enjoy a mean life expectancy of 90 years. This means,
assuming a median age for the onset of menopause of 51, that
women will spend about 40 years in menopause.
Ovarian cortical tissue freezing in order to permit future
transplantation can become a possible option for a great
number of women for postponing menopause and thus alle-
viating its sequelae. Postponing menopause means delaying
or eliminating ailments such as osteoporosis, heart disease,
insomnia, memory function, urinary incontinence and sexual
dysfunction and discomfort. However, if ovarian transplan-
tation to treat and postponemenopause is to become a reality,
both sound medical and ethical guidelines are essential.
The key moral challenge facing this treatment is uncer-
tainty as to its efﬁcacy. It is far from certain that ovarian tissue
harvested at a young age, say at 30, will still be able to func-
tion for another 20 years once re-transplanted at a later age,
say 50. “Young ovarian tissue” must be shown to be able to
maintain its own age and not adapt to the actual age of the
patient, thereby ceasing to function much earlier than
anticipated.
All the information about safety and efﬁcacy currently
available is from transplants carried out for patients af-
fected by cancer who cryopreserved ovarian tissue prior to
gonadotoxic insults (chemotherapy or radiotherapy). It has
been demonstrated that the re-transplants of ovarian tissue
work, in that menstrual cyclicity returns in the great major-
ity of women and pregnancies are achieved, with a clinical
pregnancy rate of approximately 30% (Donnez et al., 2015;
Stoop et al., 2014). However, the length of ovarian tissue
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survival is not uniform, varying from a few months to several
years. While these data are useful, they are by no means ad-
equate for undertaking the therapeutic treatment of meno-
pause. Ethically careful experiments in animals must be
undertaken to show the reliable “reversal of menopause”.
Future recipients of ovarian allograft transplants will be
both young and older, have had other children or not, may
have had a child and lost that child, may be single, married
or remarried. They sometimes have other comorbidities that
must be taken into account. Access is another key chal-
lenge. Will only wealthy women be able to beneﬁt from this
treatment? Will insurance cover a procedure that is primarily
aimed at maintaining the quality of life of women? Preven-
tive transplantation of this sort is likely to prove expensive,
but, if proven successful, could potentially save enormous
health care spending by preventing osteoporosis and conse-
quently the resultant fractures requiring treatment and
rehabilitation as well as by reducing cardiovascular risks.
In addition, should the beneﬁt of “tackling menopause”
be expanded beyond the endocrine function (i.e. hormonal
beneﬁt)? In other words, would women in their sixties be able
to and be more likely to get pregnant naturally? Should there
be any restriction of individual freedom to reproduce based
solely on a woman’s age?
The authors Andersen and Kristensen (2015) propose to re-
transplant the ovarian tissue in sites such as the forearm or
other subcutaneous tissue, thus avoiding chances of late preg-
nancies. However, this suggestion is problematic for at least
two reasons: (i) it is unknown for how long a heterotopic trans-
plant will remain functional, since the great majority of trans-
plants have been placed in orthotopic sites; and (ii) it
pre-empts the question of what if a woman does want to get
pregnant at a late age? Would orthotopic transplantation be
required? Would physicians appropriately have the author-
ity to control a competent patient’s reproductive wishes? If
women wish to have the opportunity to reproduce would ex-
isting contraceptive options need to be re-evaluated in light
of older age? Reproduction aside, other risks exist. Would
breast tissue respond differently to prolonged exposure to en-
dogenous oestrogens? What about the uterus and the cervix?
Should hysterectomy and mastectomy be a part of ovarian
transplantation to treat menopause in order to reduce the late-
onset risks of cancer?
All of these unknowns need to be studied in human sub-
jects. If animal work proves successful, the selection of sub-
jects and the consent they provide must be carefully thought
through by investigators and review committees.
No group or investigator should be involved with this form
of future allotransplantation unless there is an experi-
enced, stable team of researchers with the requisite skills and
basic research background to undertake ovarian harvest, freez-
ing and future re-grafting. A strategy for managing failure,
including adequate counselling, must be in place. A properly
educated Institutional Review Board ought to be available.
An international registry ought to be created to monitor the
initial experience with the use of transplants to treat
menopause.
In principle there are no reasons why ovarian transplants
to treat menopause ought not be pursued. But there are still
a large number of issues that need to be addressed. Animal
research and human investigation should proceed according
to morally responsible standards, avoiding premature and not
fully proven claims. First and foremost it must be shown that
this form of transplantation is really a useful tool in allevi-
ating the debilities associated with menopause without causing
or exacerbating other health risks. Only then should it to be
offered as therapy.
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